 |
197 Diseases |  |
398 Trials |
|
398 Trials |  |
21826 News |  |
| «12...245246247248249250251252253254255...266267» |
- | Yervoy (ipilimumab) / BMS
Enrollment change, Tumor-specific neoantigens, Metastases: T-Cell Responses to Neoantigens Post Treatment With Ipilimumab in Men With Metastatic Castration-Resistant Prostate Cancer (clinicaltrials.gov) - Sep 20, 2016
P2, N=30, Recruiting, Sponsor: M.D. Anderson Cancer Center
N=20 --> 30
- |||||||||| Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
New P3 trial: CA209-742: A Safety and Efficacy Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Melanoma (clinicaltrials.gov) - Sep 18, 2016
P3, N=102, Not yet recruiting, Sponsor: Bristol-Myers Squibb
- |||| Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Trial primary completion date: CheckMate 649: Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer (clinicaltrials.gov) - Sep 17, 2016
P3, N=870, Not yet recruiting, Sponsor: Bristol-Myers Squibb
N=20 --> 30 Trial primary completion date: Sep 2020 --> Mar 2019
- | vopratelimab (JTX-2011) / Concentra Biosci
New P1/2 trial, PD(L)-1 Biomarker, IO biomarker: ICONIC: JTX-2011 Alone and in Combination With Anti-PD-1 or Anti-CTLA-4 in Subjects With Advanced and/or Refractory Solid Tumors (clinicaltrials.gov) - Sep 16, 2016
P1/2, N=227, Recruiting, Sponsor: Jounce Therapeutics, Inc.
- ||| Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Enrollment change, Trial primary completion date: CheckMate 817: An Investigational Immuno-therapy Study for Safety of Nivolumab in Combination With Ipilimumab to Treat Advanced Cancers (clinicaltrials.gov) - Sep 15, 2016
P3b/4, N=500, Not yet recruiting, Sponsor: Bristol-Myers Squibb
Trial primary completion date: Sep 2020 --> Mar 2019 N=700 --> 500 | Trial primary completion date: Feb 2018 --> Oct 2020
- Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Trial initiation date: CA209-322: Nivo/Ipi Combination Therapy in Symptomatic Brain Metastases (clinicaltrials.gov) - Sep 14, 2016
P2, N=70, Recruiting, Sponsor: University Medical Center Groningen
N=700 --> 500 | Trial primary completion date: Feb 2018 --> Oct 2020 Initiation date: Jan 2016 --> Aug 2016
- Yervoy (ipilimumab) / BMS
Trial primary completion date, Metastases: Ipilimumab With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Melanoma Mets Pts (clinicaltrials.gov) - Sep 12, 2016
P=N/A, N=13, Active, not recruiting, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Initiation date: Jan 2016 --> Aug 2016 Trial primary completion date: Nov 2016 --> Jun 2017
- || Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Trial primary completion date, PD(L)-1 Biomarker, IO biomarker: CheckMate 040: An Immuno-therapy Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab or Nivolumab in Combination With Other Agents in Patients With Advanced Liver Cancer (clinicaltrials.gov) - Sep 8, 2016
P1/2, N=620, Recruiting, Sponsor: Bristol-Myers Squibb
Trial primary completion date: Nov 2016 --> Jun 2017 Trial primary completion date: Dec 2016 --> Aug 2017
- || Opdivo (nivolumab) / BMS
Trial primary completion date, MSi-H Biomarker, PD(L)-1 Biomarker: CheckMate 142: A Study of Nivolumab Alone or Nivolumab Combination Therapy in Colon Cancer That Has Come Back or Has Spread (clinicaltrials.gov) - Sep 8, 2016
P1/2, N=240, Recruiting, Sponsor: Bristol-Myers Squibb
Trial primary completion date: Dec 2016 --> Aug 2017 Trial primary completion date: Aug 2016 --> Mar 2017
- || Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Clinical: An Investigational Study of Infliximab With Prednisone or Methylprednisolone Versus Prednisone Combination Treatment in Immune Related or Severe Diarrhea in Patients Treated With Yervoy and/or Opdivo (clinicaltrials.gov) - Sep 8, 2016
P2, N=100, Not yet recruiting, Sponsor: Bristol-Myers Squibb
Trial primary completion date: Aug 2016 --> Mar 2017 Trial primary completion date: Sep 2017 --> May 2018
- |||||||||| Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
New P3 trial: CheckMate 649: Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer (clinicaltrials.gov) - Sep 8, 2016
P3, N=870, Not yet recruiting, Sponsor: Bristol-Myers Squibb
- | Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
New P2 trial, PD(L)-1 Biomarker: Ipilimumab and Nivolumab in Treating Patients With Recurrent Stage IV HER2 Negative Inflammatory Breast Cancer (clinicaltrials.gov) - Sep 8, 2016
P2, N=29, Not yet recruiting, Sponsor: Northwestern University
- Proleukin (aldesleukin) / Merck (MSD), Novartis, Iovance Biotherap, Yervoy (ipilimumab) / BMS
Enrollment open, Enrollment change, Metastases: CD8+ Antigen-Specific T Cells, Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Melanoma (clinicaltrials.gov) - Sep 7, 2016
P2, N=30, Recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Sep 2017 --> May 2018 Active, not recruiting --> Recruiting | N=14 --> 30
- Yervoy (ipilimumab) / BMS
New P1 trial, Combination therapy: Ipilimumab and Decitabine in Treating Patients With Relapsed or Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia (clinicaltrials.gov) - Sep 7, 2016
P1, N=48, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
- || Trial primary completion date, PD(L)-1 Biomarker, IO biomarker: Sequential Combo Immuno and Target Therapy (SECOMBIT) Study (clinicaltrials.gov) - Sep 2, 2016
P2, N=230, Not yet recruiting, Sponsor: Fondazione Melanoma Onlus
Active, not recruiting --> Recruiting | N=14 --> 30 Trial primary completion date: Dec 2020 --> Apr 2021
- Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Biomarker, Enrollment closed, Checkpoint inhibition, PD(L)-1 Biomarker: STARVE-PC: Biomarker-Driven Therapy With Nivolumab and Ipilimumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Expressing AR-V7 (clinicaltrials.gov) - Sep 2, 2016
P2, N=15, Active, not recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Trial primary completion date: Dec 2020 --> Apr 2021 Recruiting --> Active, not recruiting
- | plozalizumab (TAK-202) / Takeda, Ojemda (tovorafenib) / Day One Biopharma, Entyvio (vedolizumab) / Takeda
Phase classification, Checkpoint inhibition: Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination With Standard of Care Immune Checkpoint Inhibitors in Participants With Advanced Melanoma (clinicaltrials.gov) - Aug 31, 2016
P1b, N=156, Recruiting, Sponsor: Millennium Pharmaceuticals, Inc.
Recruiting --> Active, not recruiting Phase classification: P1 --> P1b
- Yervoy (ipilimumab) / BMS
Enrollment open, Monotherapy: Neoadjuvant PROSTVAC-VF With or Without Ipilimumab for Prostate Cancer (clinicaltrials.gov) - Aug 29, 2016
P2, N=75, Recruiting, Sponsor: University of California, San Francisco
Phase classification: P1 --> P1b Not yet recruiting --> Recruiting
- | Trial completion, Enrollment change, Combination therapy, Metastases: Study of Dabrafenib +/- Trametinib in Combination With Ipilimumab for V600E/K Mutation Positive Metastatic or Unresectable Melanoma (clinicaltrials.gov) - Aug 26, 2016
P1, N=38, Completed, Sponsor: GlaxoSmithKline
Not yet recruiting --> Recruiting Terminated --> Completed | N=72 --> 38
- Blincyto (blinatumomab) / Astellas, Amgen, Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
New P1 trial, Checkpoint inhibition, PD(L)-1 Biomarker, IO biomarker: NCI-2016-01300: Blinatumomab and Nivolumab With or Without Ipilimumab in Treating Patients With Poor-Risk Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia (clinicaltrials.gov) - Aug 26, 2016
P1, N=30, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
- Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
New P2 trial, Monotherapy, Tumor mutational burden, PD(L)-1 Biomarker: NCI-2016-01004: Nivolumab With or Without Ipilimumab in Treating Patients With Gastrointestinal Stromal Tumor That Is Metastatic or Cannot Be Removed by Surgery (clinicaltrials.gov) - Aug 25, 2016
P2, N=40, Not yet recruiting, Sponsor: Jonsson Comprehensive Cancer Center
- Yervoy (ipilimumab) / BMS
Trial primary completion date, Metastases: First-Line Gemcitabine, Cisplatin + Ipilimumab for Metastatic Urothelial Carcinoma (clinicaltrials.gov) - Aug 24, 2016
P2, N=36, Active, not recruiting, Sponsor: Hoosier Cancer Research Network
Terminated --> Completed | N=72 --> 38 Trial primary completion date: Jun 2016 --> Feb 2017
- |||| Erbitux (cetuximab) / Eli Lilly, Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Trial primary completion date, PD(L)-1 Biomarker, IO biomarker: CheckMate 651: Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (clinicaltrials.gov) - Aug 24, 2016
P3, N=490, Recruiting, Sponsor: Bristol-Myers Squibb
Trial primary completion date: Jun 2016 --> Feb 2017 Trial primary completion date: Jan 2020 --> Jul 2018
- Proleukin (aldesleukin) / Merck (MSD), Novartis, Iovance Biotherap, Yervoy (ipilimumab) / BMS
Enrollment closed, Enrollment change, Metastases: CD8+ Antigen-Specific T Cells, Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Melanoma (clinicaltrials.gov) - Aug 22, 2016
P2, N=14, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Jan 2020 --> Jul 2018 Recruiting --> Active, not recruiting | N=20 --> 14
- ViraferonPeg (peginterferon-?-2b) / Merck (MSD), Yervoy (ipilimumab) / BMS
Trial primary completion date: Yervoy With Sylatron Unresectable Stage 3 or 4 Melanoma (clinicaltrials.gov) - Aug 19, 2016
P1, N=31, Active, not recruiting, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Recruiting --> Active, not recruiting | N=20 --> 14 Trial primary completion date: Nov 2016 --> Mar 2017
- || Tecentriq (atezolizumab) / Roche
Trial primary completion date, Combination therapy, Metastases: A Study to Assess the Safety and Tolerability of Atezolizumab in Combination With Other Immune-Modulating Therapies in Participants With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - Aug 19, 2016
P1, N=200, Recruiting, Sponsor: Hoffmann-La Roche
Trial primary completion date: Nov 2016 --> Mar 2017 Trial primary completion date: Feb 2018 --> Feb 2019
- Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Tumor mutational burden, PD(L)-1 Biomarker, IO biomarker: Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas (clinicaltrials.gov) - Aug 19, 2016
P1/2, N=352, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Feb 2018 --> Feb 2019 N=242 --> 352
- ||| Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Enrollment open: RATIO: Rational Approach To Immuno-Oncology (clinicaltrials.gov) - Aug 19, 2016
P=N/A, N=100, Recruiting, Sponsor: AHS Cancer Control Alberta
N=242 --> 352 Not yet recruiting --> Recruiting
- |||||||||| Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
New P3 trial: CheckMate 649: Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer (clinicaltrials.gov) - Aug 19, 2016
P3, N=750, Not yet recruiting, Sponsor: Bristol-Myers Squibb
- |||| Yervoy (ipilimumab) / BMS
Trial completion, Trial primary completion date, Metastases: Ipilimumab + Temozolomide in Metastatic Melanoma (clinicaltrials.gov) - Aug 17, 2016
P2, N=64, Completed, Sponsor: M.D. Anderson Cancer Center
Not yet recruiting --> Recruiting Active, not recruiting --> Completed | Trial primary completion date: May 2017 --> Aug 2016
- Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Enrollment open, Trial initiation date, PD(L)-1 Biomarker: Check Point Inhibition After Autologous Stem Cell Transplantation in Patients at High Risk of Post Transplant Recurrence (clinicaltrials.gov) - Aug 16, 2016
P1/2, N=42, Recruiting, Sponsor: Hackensack University Medical Center
Active, not recruiting --> Completed | Trial primary completion date: May 2017 --> Aug 2016 Not yet recruiting --> Recruiting | Initiation date: Mar 2016 --> Jun 2016
- ||||| Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
New P2 trial, Checkpoint inhibition: CheckPAC: Immune Checkpoint Inhibition in Combination With Radiation Therapy in Pancreatic Cancer or Biliary Tract Cancer Patients (clinicaltrials.gov) - Aug 15, 2016
P2, N=80, Not yet recruiting, Sponsor: Herlev Hospital
- Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Tumor mutational burden: SWOG S1609: Nivolumab and Ipilimumab in Treating Patients With Rare Tumors (clinicaltrials.gov) - Aug 13, 2016
P=N/A, N=334, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting | Initiation date: Mar 2016 --> Jun 2016 Initiation date: Jun 2016 --> Jun 2017
- Yervoy (ipilimumab) / BMS
Trial completion, Trial primary completion date, Metastases: Ipilimumab in Patients With Advanced Melanoma and Spontaneous Preexisting Immune Response to NY-ESO-1 (clinicaltrials.gov) - Aug 12, 2016
P2, N=25, Completed, Sponsor: National Center for Tumor Diseases, Heidelberg
Initiation date: Jun 2016 --> Jun 2017 Active, not recruiting --> Completed | Trial primary completion date: Jun 2015 --> Aug 2016
- | Firmagon (degarelix) / Astellas, Ferring, Yervoy (ipilimumab) / BMS
Enrollment closed, Enrollment change, Metastases: Combining Ipilimumab, Degarelix, and Radical Prostatectomy in Men With Newly Diagnosed Metastatic Castration Sensitive Prostate Cancer or Ipilimumab and Degarelix in Men With Biochemically Recurrent Castration Sensitive Prostate Cancer After Radical Prostatectomy (clinicaltrials.gov) - Aug 11, 2016
P2, N=16, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Active, not recruiting --> Completed | Trial primary completion date: Jun 2015 --> Aug 2016 Recruiting --> Active, not recruiting | N=53 --> 16
- Avastin (bevacizumab) / Roche, Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Enrollment open: Hypofractionated Stereotactic Irradiation With Nivolumab, Ipilimumab and Bevacizumab in Patients With Recurrent High Grade Gliomas (clinicaltrials.gov) - Aug 11, 2016
P1, N=26, Recruiting, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Recruiting --> Active, not recruiting | N=53 --> 16 Not yet recruiting --> Recruiting
- |||||||||| Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
New P3 trial, PD(L)-1 Biomarker: CheckMate 722: A Study of Nivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Who Failed 1L or 2L EGFR Tyrosine Kinase Inhibitor (TKI) Therapy (clinicaltrials.gov) - Aug 11, 2016
P3, N=465, Not yet recruiting, Sponsor: Bristol-Myers Squibb
- Yervoy (ipilimumab) / BMS
Trial primary completion date, Metastases: Phase II Trial of Stereotactic Body Radiotherapy Followed by Ipilimumab in Treating Patients With Stage IV Melanoma (clinicaltrials.gov) - Aug 10, 2016
P2, N=40, Recruiting, Sponsor: University of Washington
Not yet recruiting --> Recruiting Trial primary completion date: Sep 2016 --> Mar 2017
- Trial initiation date, Trial primary completion date: Adoptive Therapy Using Antigen-Specific CD4 T-Cells (clinicaltrials.gov) - Aug 10, 2016
P1, N=12, Not yet recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Sep 2016 --> Mar 2017 Initiation date: May 2016 --> Dec 2016 | Trial primary completion date: May 2019 --> Dec 2019
- Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Enrollment open, Checkpoint inhibition: Pilot Study of the Safety/Efficacy of Combination Checkpoint Blockade + External Beam Radiotherapy in Stage IV Melanoma (clinicaltrials.gov) - Aug 10, 2016
P1, N=18, Recruiting, Sponsor: Ludwig Institute for Cancer Research
Initiation date: May 2016 --> Dec 2016 | Trial primary completion date: May 2019 --> Dec 2019 Not yet recruiting --> Recruiting
- ||| Opdivo (nivolumab) / BMS
Enrollment change, MSi-H Biomarker, PD(L)-1 Biomarker: CheckMate 142: A Study of Nivolumab Alone or Nivolumab Combination Therapy in Colon Cancer That Has Come Back or Has Spread (clinicaltrials.gov) - Aug 9, 2016
P1/2, N=240, Recruiting, Sponsor: Bristol-Myers Squibb
Not yet recruiting --> Recruiting N=96 --> 240
- || Trial primary completion date: FRACTION-Lung: An Investigational Immuno-therapy Study to Test Combination Treatments in Patients With Advanced Non-Small Cell Lung Cancer (clinicaltrials.gov) - Aug 9, 2016
P2, N=504, Recruiting, Sponsor: Bristol-Myers Squibb
N=96 --> 240 Trial primary completion date: Apr 2020 --> Apr 2021
- |||||| Erbitux (cetuximab) / Eli Lilly, Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Enrollment open, PD(L)-1 Biomarker, IO biomarker: CheckMate 651: Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (clinicaltrials.gov) - Aug 9, 2016
P3, N=490, Recruiting, Sponsor: Bristol-Myers Squibb
Trial primary completion date: Apr 2020 --> Apr 2021 Not yet recruiting --> Recruiting
- Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Biomarker, Trial primary completion date, PD(L)-1 Biomarker: Lung-Map Sub-Study: Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers (clinicaltrials.gov) - Aug 8, 2016
P3, N=350, Recruiting, Sponsor: Southwest Oncology Group
Not yet recruiting --> Recruiting Trial primary completion date: Apr 2022 --> Dec 2019
- || Yervoy (ipilimumab) / Ono Pharma, BMS
Trial primary completion date: Study of Autoimmune Disease Complications Following Ipilimumab Treatment Among Melanoma Patients With Underlying Autoimmune Diseases (clinicaltrials.gov) - Aug 8, 2016
P=N/A, N=370, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Trial primary completion date: Apr 2022 --> Dec 2019 Trial primary completion date: Jul 2016 --> Dec 2018
- | Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
New P1/2 trial: NIVIPIT: A Trial Evaluating the Safety & Efficacy of Intra-Tumoral Ipilimumab in Combination With Intra-venous Nivolumab in Patients With Metastatic Melanoma (clinicaltrials.gov) - Aug 5, 2016
P1/2, N=65, Recruiting, Sponsor: Gustave Roussy, Cancer Campus, Grand Paris
- Yervoy (ipilimumab) / Ono Pharma, BMS
New trial, Adverse events: Yervoy Pregnancy Surveillance Study (clinicaltrials.gov) - Aug 3, 2016
P=N/A, N=10, Not yet recruiting, Sponsor: Bristol-Myers Squibb
- Yervoy (ipilimumab) / BMS
Enrollment change, Trial termination, Metastases: Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage lV Malignant Melanoma (clinicaltrials.gov) - Jul 29, 2016
P2, N=12, Terminated, Sponsor: Bristol-Myers Squibb
Trial primary completion date: Jul 2016 --> Dec 2018 N=30 --> 12 | Recruiting --> Terminated; Slow accrual
- | Intron A (interferon ?-2b) / Merck (MSD), Biogen, Yervoy (ipilimumab) / BMS
Enrollment closed: E1609: Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery (clinicaltrials.gov) - Jul 28, 2016
P3, N=1500, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
N=30 --> 12 | Recruiting --> Terminated; Slow accrual Recruiting --> Active, not recruiting
- || Opdivo (nivolumab) / BMS
Monotherapy, PD(L)-1 Biomarker, IO biomarker: CheckMate 039: An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma (clinicaltrials.gov) - Jul 28, 2016
P1, N=375, Recruiting, Sponsor: Bristol-Myers Squibb
Recruiting --> Active, not recruiting Trial primary completion date: Jul 2017 --> Oct 2018